Andrew Fisher Joins Verona Pharma as General Counsel
March 04, 2024 02:00 ET
|
Verona Pharma plc
Verona Pharma announces Mr. Andrew Fisher has today joined the Company as General Counsel, and member of the Executive Management Team.
Michael Austwick Joins Verona Pharma as Non-Executive Director
February 01, 2024 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”) announces Mr. Michael Austwick has today joined the board as a Non-Executive Director. ...
Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at CHEST 2023
October 03, 2023 02:00 ET
|
Verona Pharma plc
PDUFA Target Action Date of June 26, 2024 Pooled analysis and subgroup data further support potential of ensifentrine, an investigational, novel, selective, dual inhibitor of PDE3 and PDE4 LONDON...
Verona Pharma Announces the US FDA has Accepted the New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPD
September 11, 2023 02:00 ET
|
Verona Pharma plc
PDUFA Target Action Date of June 26, 2024 Ensifentrine, if approved, is expected to be the first novel mechanism available for the maintenance treatment of COPD in more than a decade LONDON and...
Verona Pharma plc: PDMR Dealing
August 09, 2019 04:35 ET
|
Verona Pharma plc
LONDON, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
Verona Pharma Reports Positive Phase 2 Results with Dry Powder Inhaler Formulation of Ensifentrine in COPD
August 05, 2019 02:00 ET
|
Verona Pharma plc
LONDON, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces positive Phase 2 data...
Verona Pharma Strengthens its Clinical Team Ahead of Phase 3 Development of Ensifentrine
June 25, 2019 02:00 ET
|
Verona Pharma plc
LONDON, June 25, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces two senior...
Verona Pharma to Present at H.C. Wainwright Global Life Sciences Conference
March 26, 2019 03:00 ET
|
Verona Pharma plc
LONDON, March 26, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (NASDAQ: VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing...
Dr. Martin Edwards Joins Verona Pharma as Non-Executive Director
March 21, 2019 03:00 ET
|
Verona Pharma plc
LONDON, March 21, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing...